Ke Ding

This inventor holds 15 USPTO granted patents and 10 published patent applications and 6 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Chinese Academy of Sciences, University of Michigan, Jinan University. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ke Ding. Retrieved from https://idiyas.com/inventor/ke-ding-9sy1hv8f

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 10)

% Patents Active = 60.0

EPO Patents = 6 (Patent Applications = 15)

Average Co-Inventor Count = 6.9

ph-index = 4

Forward Citations = 90(Granted Patents)

Location History:

Guangzhou, CN (2010 - 2019)
Guangdong, CN (2014 - 2023)

Company Filing History:

8 out of 3,370

Chinese Academy of Sciences

patents

4 out of 3,550

University of Michigan

Auckland Uniservices Limited

patents

5. 1 out of 1

Guangzhou Eggbio Co., Ltd.

patent

6. 1 out of 2

Guangzhou Institute of Biomedicine and Health

patents

7. 1 out of 1

Guangzhou Salustier Biosciences Co., Ltd.

patent

8. 1 out of 224

Saint Louis University

patents

9. 1 out of 9

Shanghai Haihe Pharmaceutical Co., Ltd.

patents

10. 1 out of 1

Shenzhen Newdel Biotech Co., Ltd.

patent

11. 1 out of 5,645

The University of Texas System

patents

where one patent can have more than one assignee

Years Active: 2010-2026

Loading Chart...

Areas of Expertise:

Aminopyrimidine Compounds

Alkynylphenylbenzamide

FGFR Kinase Inhibitors

Quinolone Derivatives

Discoidin Domain Receptor

Pyrazolo Compounds

NSAID Coupling Compounds

Malaria Treatment

MDM2 Inhibitors

Estrogen-Related Modulators

Heterocyclic Compounds

Pharmaceutical Compositions

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12753185 - 2-aminopyrimidine compound and pharmaceutical composition thereof and application thereof (2026-10-06),

2. 11834454 - Alkynylphenylbenzamide compounds and applications thereof (2023-12-05),

3. 11192890 - FGFR kinase inhibitors and pharmaceutical uses (2021-12-07),

4. 10683278 - Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof (2020-06-16),

5. 10370360 - Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof (2019-08-06),

6. 10155756 - Pyrazolo[1,5-A]pyridine compounds and use thereof (2018-12-18),

7. 10059694 - 2-aminopyrimidine compound and pharmaceutical composition and use thereof (2018-08-28),

8. 9452220 - Coupling compounds of NSAID anti-inflammatory and analgesic drugs and EGFR kinase inhibitors, synthesis methods and applications thereof (2016-09-27),

9. 9353089 - Compositions and methods for the treatment of malaria (2016-05-31),

10. 8901117 - Small molecule inhibitors of MDM2 and the uses thereof (2014-12-02),

11. 8853221 - Compounds of estrogen-related receptor modulators and the uses thereof (2014-10-07),

12. 8846671 - Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof (2014-09-30),

13. 8742121 - Process for the preparation of small molecule inhibitors of MDM2 and intermediates used therein (2014-06-03),

14. 8088931 - Small molecule inhibitors of MDM2 and the uses thereof (2012-01-03),

15. 7759383 - Small molecule inhibitors of MDM2 and the uses thereof (2010-07-20),

Title: Innovator Spotlight: Ke Ding - Pioneering Developments in Pharmaceutical Innovation

Introduction:

Meet Ke Ding, a visionary inventor from Guangzhou, China, whose groundbreaking work in the field of pharmaceuticals has led to 13 patented inventions. His focus on developing cutting-edge solutions for hyper-proliferative diseases has earned him recognition worldwide.

Latest Patents:

Ke Ding's latest patents include FGFR kinase inhibitors for treating various hyper-proliferative diseases such as retinopathy, psoriasis, and rheumatoid arthritis. Additionally, his work on substituted quinolone derivatives has shown promising results in the prevention and treatment of tumors, particularly as protein kinase inhibitors effective in inhibiting tumor cell proliferation and invasion.

Career Highlights:

Ke Ding has made significant contributions to the field of pharmaceuticals through his work at prestigious institutions such as the Guangzhou Institutes of Biomedicine and Health at the Chinese Academy of Sciences, and the University of Michigan. His expertise and dedication to advancing medical research have led to the development of innovative therapies for a range of challenging diseases.

Collaborations:

Throughout his career, Ke Ding has collaborated with esteemed colleagues such as Zhengchao Tu and Shaomeng Wang. Together, they have worked on pioneering projects that have advanced the understanding and treatment of hyper-proliferative diseases, setting new standards for pharmaceutical innovation.

Conclusion:

In conclusion, Ke Ding stands as a trailblazing inventor in the field of pharmaceutical innovation, with a remarkable portfolio of patented inventions that have the potential to revolutionize medical treatment. His collaborative spirit and relentless pursuit of scientific excellence underscore his commitment to improving global healthcare outcomes.

Profile summary based on public USPTO records.